Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Atara Biotherapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ATRA
Nasdaq
8731
https://www.atarabio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Apr 5th, 2024 8:01 pm
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
- Mar 28th, 2024 1:40 pm
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
- Mar 28th, 2024 12:30 pm
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
- Feb 29th, 2024 2:05 pm
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
- Feb 28th, 2024 9:30 pm
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
- Feb 14th, 2024 2:00 pm
After losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gain
- Feb 3rd, 2024 1:54 pm
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
- Jan 31st, 2024 11:30 pm
Seth Klarman's Exit from Atara Biotherapeutics Inc
- Jan 11th, 2024 6:26 am
Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding
- Jan 11th, 2024 6:26 am
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
- Jan 8th, 2024 2:00 pm
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 8th, 2024 1:00 pm
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 4th, 2024 9:01 pm
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
- Dec 20th, 2023 9:01 pm
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
- Dec 11th, 2023 5:00 pm
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec 1st, 2023 9:01 pm
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
- Nov 29th, 2023 11:05 pm
Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
- Nov 24th, 2023 5:29 pm
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
- Nov 22nd, 2023 9:01 pm
Billionaire Seth Klarman’s Biotech Stock Picks
- Nov 22nd, 2023 2:14 pm
Scroll